This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by López de Maturana, R. Articles by Millar, R. P. Search for Related Content PubMed PubMed Citation Articles by López de Maturana, R. Articles by Millar, R. P.

Gonadotropin-Releasing Hormone Analog Structural Determinants of Selectivity for Inhibition of Cell Growth: Support for the Concept of Ligand-Induced Selective Signaling

Ardana Bioscience (R.L.d.M., R.P.M.), Edinburgh EH3 7HA, United Kingdom; Medical Research Council Human Reproductive Sciences Unit (R.L.d.M., A.J.P., Z.-L.L., L.D., S.M., K.M., R.P.M.), The Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom; and Cancer Research Center (S.P.L.), University of Edinburgh, Edinburgh EH4 2XR, United Kingdom

Address all correspondence and requests for reprints to: Prof. R. P. Millar, MRC Human Reproductive Sciences Unit, The Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom. E-mail: r.millar{at}hrsu.mrc.ac.uk.

GnRH and its receptor are expressed in human reproductive tract cancers, and direct antiproliferative effects of GnRH analogs have been demonstrated in cancer cell lines. The intracellular signaling responsible for this effect differs from that mediating pituitary gonadotropin secretion. The GnRH structure-activity relationship is different for the two effects. Here we report a structure-activity relationship study of GnRH agonist antiproliferative action in model cell systems of rat and human GnRH receptors stably expressed in HEK293 cells. GnRH II was more potent than GnRH I in inhibiting cell growth in the cell lines. In contrast, GnRH I was more potent than GnRH II in stimulating inositol phosphate production, the signaling pathway in gonadotropes. The different residues in GnRH II (His⁵, Trp⁷, Tyr⁸) were introduced singly or in pairs into GnRH I. Tyr⁵ replacement by His⁵ produced the highest increase in the antiproliferative potency of GnRH I. Tyr⁸ substitution of Arg⁸ produced the most selective analog, with very poor inositol phosphate generation but high antiproliferative potency. In nude mice bearing tumors of the HEK293 cell line, GnRH II and an antagonist administration was ineffective in inhibiting tumor growth, but D-amino acid stabilized analogs (D-Lys⁶ and D-Arg⁶) ablated tumor growth. Docking of GnRH I and GnRH II to the human GnRH receptor molecular model revealed that Arg⁸ of GnRH I makes contact with Asp³⁰², whereas Tyr⁸ of GnRH II appears to make different contacts, suggesting these residues stabilize different receptor conformations mediating differential intracellular signaling and effects on gonadotropin and cell growth. These findings provide the basis for the development of selective GnRH analog cancer therapeutics that directly target tumor cells or inhibit pituitary gonadotropins or do both.

This article has been cited by other articles:

				P. Chen and S. M. Moenter GABAergic Transmission to Gonadotropin-Releasing Hormone (GnRH) Neurons Is Regulated by GnRH in a Concentration-Dependent Manner Engaging Multiple Signaling Pathways J. Neurosci., August 5, 2009; 29(31): 9809 - 9818. [Abstract] [Full Text] [PDF]